Theravance Biopharma, Inc.

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $48.6m $15.4m $60.4m $73.4m $71.9m $55.3m $51.3m $57.4m $64.4m $107.5m
Cost of Goods and Services Sold $2.9m $6.0m $23.7m $28.8m $28.2m $21.7m $20.1m $43.4m $42.2m $37.4m
Gross Profit (Calculated) (derived) $45.8m $9.4m $36.7m $44.6m $43.7m $33.6m $31.2m $14.1m $22.2m $70.0m
Operating Expenses $229.1m $275.5m $299.1m $325.3m $369.6m $313.1m $143.3m $113.5m $111.3m $111.1m
Operating Income (Loss) ($180.5m) ($260.1m) ($238.8m) ($251.9m) ($297.8m) ($257.8m) ($92.0m) ($56.0m) ($46.9m) ($3.6m)
Additional Financial Items
Foreign Currency Transaction Gain (Loss), before Tax ($900k) $900k $60k ($100k) ($100k)
Income (Loss) from Continuing Operations before Income Taxes, Domestic $180.6m $199.6m $92.8m $49.3m $44.6m $20.9m
Income (Loss) from Continuing Operations, Per Basic Share ($1) ($1)
Income (Loss) from Continuing Operations, Per Diluted Share ($1) ($1)
Income (Loss) from Equity Method Investments $11.2m $33.7m $68.4m $104.0m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest ($180.6m) ($271.7m) ($226.1m) ($241.7m) ($286.5m) ($199.6m) ($92.8m) ($49.3m) ($44.6m) $129.2m
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent ($92.8m) ($55.2m)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $965.0m
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent $965.0m
Net Income (Loss) Attributable to Parent ($190.7m) ($285.4m) ($215.5m) ($236.5m) ($278.0m) ($199.4m) $872.1m ($55.2m) ($56.4m) $105.9m
Net Income (Loss) Available to Common Stockholders, Basic ($190.7m) ($285.4m) ($215.5m) ($236.5m) ($278.0m) ($199.4m) $872.1m ($55.2m) ($56.4m) $105.9m
Earnings Per Share, Basic ($2.87) $11.85 ($1.00) ($1.15) $2.10
Earnings Per Share, Diluted ($2.87) $11.85 ($1.00) ($1.15) $2.06
Weighted Average Number of Shares Outstanding, Basic 56.5m 62.8m 69.5m 73.6m 55.3m 48.8m 50.3m
Weighted Average Number of Shares Outstanding, Diluted 55.6m 62.3m 69.5m 73.6m 55.3m 48.8m 51.5m
Research and Development Expense $141.7m $173.9m $201.3m $219.2m $261.0m $193.7m $63.4m $40.6m $37.6m $37.4m
Selling, General and Administrative Expense $84.5m $95.6m $97.1m $106.1m $108.7m $99.3m $67.1m $70.1m $69.2m $73.7m
Other Nonoperating Income (Expense) $1.3m $5.0m $12.0m $8.4m $2.8m $1.1m $8.5m $9.1m $4.9m $10.2m
Interest Expense (non-operating) $2.5m $2.5m
Current Income Tax Expense (Benefit) $10.1m $13.7m ($10.6m) ($5.2m) ($8.5m) ($151k) $9k ($2.7m) $19.4m $34.9m
Interest Expense $1.4m $8.5m $10.5m $31.9m $44.6m $46.9m $6.4m $2.4m
Interest Expense, Debt $9.3m $28.8m $42.6m $44.7m $4.9m
Marketing and Advertising Expense $5.1m
Income Tax Expense (Benefit) $10.1m $13.7m ($10.6m) ($5.2m) ($8.5m) ($151k) $9k $5.9m $11.8m $23.4m